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INTRODUCTION 
There are billions of cells in the human body. From the fertilized 
egg to death in old age, a human being is the product of billions of cell 
divisions. Like all complex systems, growth control can go wrong, 
resulting in the loss of normal territorial restraint, producing a family of 
cells that can multiply indefinitely- termed cancerous growth. It is not just 
the local growth of tumour cells that makes them so lethal but it is their 
spread, directly through invasion and by metastases to other sites of the 
body. 
 
The prevalence cancer is often strikingly dissimilar in different 
groups of population, varies greatly from one community to another, and 
differs in different communities in the same geographical location, 
depending on the practices and lifestyles of the people in that location. 
Among various cancers affecting the human body, oral cancer accounts 
nearly one third of all. Oral cancer is one of the ten leading cancers in the 
world and shows marked geographic differences in occurrence. 
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Several factors have been considered responsible for the 
development of oral cancer. The use of tobacco, ill-fitting dentures, poor 
oral hygiene, syphilis, inadequate diet, malnutrition and chronic irritation 
from rough or broken teeth have been shown to be more frequent in oral 
cancer patients.  However, among these factors use of tobacco stands first. 
More people use tobacco today than at any other time in human history. 
Tobacco is amongst the most addictive product known and this tobacco 
dependence is a progressive, chronic and relapsing disorder. Tobacco is 
the biggest killer, much bigger in dimension than all other forms of 
pollution. Tobacco kills more than AIDS, legal and  illegal drugs, road 
accidents, murder and suicides combined. The smokers have markedly 
increased risk of multiple cancers, heart diseases, and strokes and if they 
chew tobacco, the risk of cancer of the lip, tongue and mouth increases. 
The American Cancer Society's most recent estimates for oral cavity and 
oropharyngeal cancers in the United States are for 2009 about 28,500 new 
cases (20,100 in men and 8,400 in women) of oral cavity and 
oropharyngeal cancer; an estimated 6,100 people (4,200 men and 1,900 
women) will die of these cancers 
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When patients newly diagnosed with oral and oropharyngeal cancers are 
carefully examined, about 15% will have another cancer in a nearby area 
such as the larynx, the esophagus or the lung. Of those who are cured of 
their oral or oropharyngeal cancer, 10% to 40% will develop another 
cancer later. Often, the cancer will occur in one of these organs or a new 
cancer will develop in the throat or mouth. For this reason, patients with 
oral and oropharyngeal cancer need to have follow-up exams for the rest 
of their lives. They also need to avoid using tobacco and alcohol, which 
increase the risk for these second cancers. 
It is estimated that there are approximately 2 to 2.5 million cases of cancer 
in India at any given point of time and that there are 7,00,000 new cancer 
patients diagnosed every year in India. Tobacco-related cancer (TRC) 
cases constitute 48.2% in men and 20.1% in women of the total cancers 
seen in India per year. The age-adjusted rate (AAR) of TRC ranges from 
44 to 67 among males and from 23 to 27 among females in different 
registries in India. The lifetime cumulative risk (0-74 years) of cancer in 
Madras is one in eight with age-adjusted rate (AAR) of oral cavity of 9.4. 
In India, oral cancers account for four in 10 of all cancers.  
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In a developing country like India, the second most populous 
country in the world, health is major issue. It is especially true in the rural 
population. The illiteracy, ignorance, poverty, lack of awareness, lack of 
access to treatment facilities including preventive measures and unequal 
distribution of health care facilities makes it a much more complicated 
and complex pubic health issue. Oral cancer presents a major health 
problem in India (15-70% of all cancers diagnosed are found in the oral 
cavity). 
 
A beedi is an Indian form of cheap cigarette, a smoke for the 
common man in the country. It is made by rolling between the fingers a 
rectangular dried piece of Temburni (Diospyrosmelanoxylon), also called 
Tendu leaf with 0.30-0.36 gram of tobacco and securing the roll with a 
thread. The length of a beedi varies from 4 cm to 7.5 cm. Chutta is a more 
coarsely prepared cheroot and is often smoked with the burning end inside 
the mouth. 
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ANATOMY 
ORAL CAVITY AND OROPHARYNX 
ANATOMY OF ORAL CAVITY: 
 The oral cavity extends from the skin and vermillion junction of the 
lips to the junction of the hard and soft palate above and to the linea 
terminalis or line of circumvallate papillae on the tongue below.  
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Lips: 
 It is well defined into upper and lower lips that are joined laterally 
at the commissures.  In the midline of the upper lip is the philtrum.  They 
are supplied by the facial artery or branches of the external carotid 
system.  Local spread of the tumour can occur along the adventitia of the 
facial vessels. 
 Lower lip is supplied by branches of the mandibular nerve and the 
upper lip by maxillary nerve.  
 
Buccal Mucosa:  
  This area includes all the membranous lining of the inner surface of 
the cheeks and lips.  It is supplied by the facial artery and maxillary 
artery.  The nerve supply is by the mandibular nerve via the buccal nerve.  
 
Upper Alveolar Ridge:  
 It is the alveolar process of the maxilla and its covering mucosa.  
The arterial supply is by the maxillary artery and the nerve supply is by 
branches of the maxillary nerve.   
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Lower Alveolar Ridge: 
 This includes alveolar process of the mandible and the covering 
mucosa.  It is supplied by the lingual artery and maxillary artery.  The 
nerve supply is by the mandibular nerve.  
 
Retromolar Trigone:  
 This area is the attached mucosa overlying the ascending rami of 
the mandible from the level of the posterior surface of the last molar tooth 
to the apex superiorly, adjacent to the tuberosity of the maxilla. The 
arterial and nerve supply is similar to that of the lower alveolar ridge.   
 
Floor of the Mouth:  
 The floor is the semilunar space of the mylohyoid and hypoglossal 
muscles, extending from the inner surface of the lower alveolar ridge to 
the undersurface of the lower alveolar ridge to the undersurface of the 
tongue.  It is supplied by the lingual artery through the dorsal lingual 
branches and sublingual artery and the inferior alveolar artery through its 
lingual branches. The nerve supply is by the mandibular nerve through the 
buccal nerve.  
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Hard Palate: 
 This is a semi lunar area between the upper alveolar ridge and the 
mucous membranes covering the palatine process of the maxillary bones. 
It is supplied by greater palatine artery. The nerve supply is by the greater 
palatine and nasopalatine branches of the pterygopalatine ganglion 
(maxillary nerve).  
Anterior 2/3rd of the Tongue:  
 The anterior 2/3rd of the tongue is freely mobile and extends 
anteriorly from the line of circumvallate papillae to the undersurface of 
the tongue at the junction of the floor of the mouth.  It consists of intrinsic 
and extrinsic muscles supplied by sublingual artery and inferior alveolar 
artery through lingual branches.  The nerve supply is by the mandibular 
nerve through the lingual nerve, while taste sensation is supplied by the 
chorda tympani nerve.  All the muscles are supplied by the hypoglossal 
nerve except for palatoglossus which is supplied by the pharyngeal 
plexus.  
 
Lymphatic Drainage of the Oral Cavity:  
 The central part of the lower lip drains into the submental nodes 
while the rest of the lips drain into the submandibular lymph nodes on 
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either side.  The buccal mucosa drains mainly into the submandibular and 
preauricular lymph nodes as well as into buccal and mandibular lymph 
nodes.  The anterior part of the lower alveolar ridge has a similar 
lymphatic drainage. The upper alveolar ridge drains into the 
submandibular lymph nodes.  The hard palate drains into the upper deep 
cervical and retropharyngeal nodes.  The tip of the oral tongue drains 
bilaterally into submental lymph nodes.  Whereas the right and left halves 
drain mainly to their respective submandibular lymph nodes.  A few 
central lymphatics drain bilaterally.  
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ANATOMY OF OROPHARYNX 
 Oropharynx extends from the junction of the hard and soft palate in 
the superior aspect, the palatoglossal folds in the lateral aspect to the level 
of the floor of the valleculae. 
Base of Tongue: 
 Extends from the circumvallate papillae to the vallecula covered by 
non keratinized squamous cell epithelium, lymphoid tissue present below 
the mucosa forms a part of the Waldeyer’s ring. It is continuous with the 
tonsillar fossa through the tonsillolingual sulcus.  
 
Tonsillar Pillars and Tonsils:  
 The tonsillar pillars are formed by the palatoglossus fold anteriorly 
and the palatopharyngeus fold posteriorly, covered by non-keratinising 
stratified squamous epithelium. Tonsils are oval masses of specialized 
sub-epithelial lymphoid tissue situated in the triangular tonsillar fossa 
between the diverging palatopharyngeal and palatoglossal folds.  The 
medial wall has crypts, the surface of which is lined by non – keratinized 
stratified squamous epithelium.  
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Soft Palate: 
  It is a mobile, flexible partition between the nasopharyngeal airway 
and the oropharyngeal food passage.  It forms the roof of the oropharynx. 
It is formed by the palatine aponeurosis which joins in median raphae. 
Other muscles which constitute the soft palate include levator palati, 
palatoglossus, palatopharyngeus and the uvular muscle.   
 
Blood Supply of Oropharynx:  
Arterial Supply: 
1. Ascending pharyngeal artery from the external carotid artery  
2. Ascending palatine and tonsillar branches of the facial artery 
3. Greater palatine and pterygoid branches of the maxillary artery  
Venous Drainage:  
1 Internal submucous plexus of veins 
2 External pharyngeal plexus  
3 Communicating branches between the external pharyngeal plexus 
and veins of the dorsum of the tongue, superior laryngeal veins and 
oesophageal veins.   
The pharyngeal plexus drains into the internal jugular vein and anterior 
facial veins.  It also communicates with the pterygoid plexus.   
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Lymphatic Drainage:  
 All the lymphatics drain into the upper deep cervical lymph nodes.  
 
Nerve Supply  
 All the motor, sensory and autonomic fibres supplying the 
oropharynx are derived from the pharyngeal plexus situated in the 
buccophayngeal fascia.  In addition secretomotor fibres are supplied 
from the pterygopalatine ganglion.  
 
Anatomy of salivary glands 
Distribution  
       There are three pairs of major salivary glands, the parotid, 
submandibular and sublingual, each situated outside the oral cavity but 
connected to it by a duct or system of ducts. In addition to these, there are 
collections of salivary tissue just below or within the oral mucosa itself. 
This tissue is collectively termed the minor salivary glands. 
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The parotid glands  
Gross morphology 
 Each parotid gland is a slender, lobulated, lozenge shaped structure 
which has been likened to an inverted pyramid. It has a small superior 
surface and much larger anteromedial, posteromedial and superficial 
faces.  It anterior border overlies and is densely adherent to the posterior 
part of the masseter muscle.  Superiorly this border is limited by the 
zygomatic arch, whereas the inferior extent is more variable. Its posterior 
border abuts onto the tragal cartilage superiorly and extends inferiorly to 
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overlap the upper part of the sternomastoid muscle.  The superior surface 
is related to the external auditory meatus and the posterior aspect of the 
temporomandibular joint, while its anteromedial surface is attached to the 
masseter muscle, posterior border of the mandibular ramus and the medial 
pterygoid muscle. The posteromedial surface is grooved by the posterior 
belly of the digastric mucsle, styloid process and its attached muscles and 
ligaments.   
 
The Capsule  
 The superficial surface of the parotid gland is covered by skin and 
fascia.  Inferiorly it is also covered by the posterior border of the platysma 
muscle.  The fascia condenses immediately over the gland to form its 
capsule, which for the most part is thick, tough and inelastic, although 
inferiorly it becomes thinner. Within the capsule are the superficial 
parotid lymph nodes and the greater auricular nerve. 
 
The parotid duct 
The tree like tributary ducts join near the anterior border of the gland and 
leave it to pass forward over the superficial surface of the masseter along 
an imaginary line drawn from the angle of the mouth to the attachment of 
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the earlobe. The Stenson’s duct opens into the mouth at the parotid papilla 
opposite the upper second molar tooth. 
 
Submandibular glands 
It consists of a large superficial and a smaller deep lobe which are 
continuous around the posterior border of the mylohyoid muscle. It fills 
the submandibular triangle in the neck. The medial aspect of the 
superficial part lies on the inferior surface of the mylohyoid muscle; the 
lateral surface is covered by the body of the mandible, while its inferior 
surface lies on both bellies of the digastric muscle. Its inferior surface is 
covered by the platysma muscle, deep fascia and skin. The deep part of 
the gland lies on the hyoglossus muscle where it is related superiorly to 
the lingual nerve and inferiorly to the hypoglossal nerve and deep lingual 
vein. The capsule of the gland is well defined. 
 
The submandibular duct 
Wharton’s duct is formed by the union of several tributaries and is 
about 5cm in length. It emerges from the deep surface to run in the space 
between the hyoglossus and mylohyoid muscles to open into a papilla to 
the side of the lingual frenulum. 
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The sublingual glands 
They lie in the anterior part of the floor of the mouth, between the 
mucous membrane, the mylohyoid muscle and the body of the mandible 
close to the symphysis, where each may produce a small depression-the 
sublingual fossa. The gland has numerous excretory ducts which either 
open directly onto the mucous membrane or into the terminal part of the 
submandibular duct.  
 
Special features of individual glands  
Parotid: In man as in most mammals the secretory acini of the parotid 
gland consist entirely of serous cells. The parotid secretion is accordingly 
a watery serous secretion low in mucin and high in enzymes. The 
intercalated ducts are long and there are numerous striated ducts.  
 
Submandibular: This is a mixed gland with predominantly serous 
secretory units. Some of the mucous acini have serous cells at their 
terminal ends, some have serous demilunes. The ratio of serous to mucous 
cells is 4:1. The intercalated ducts are short and narrow. The intralobular 
ducts are branched, longer and more numerous than in the parotid duct 
system and are lined by two types of cell.  
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Sublingual gland: This is a complex of small glands although described 
as a single gland. The acini are mainly pure mucous though some have 
large serous crescents. There are very few pure serous acini. The ratio of 
serous to mucous cellular elements is 1:4. The intercalated ducts are very 
short and some acini open directly into striated intralobular ducts. These 
intralobular ducts have only one type of ‘striated’ cell. The glands open 
by some extalobular ducts into the floor of the mouth.  
 
Accessory salivary glands 
Many small glands are present in the mucosa and submucosa of the oral 
cavity. These include.  
1. In the oral vestibule: labial glands in the upper and lower lips and 
buccal glands in the cheeks. These have mixed serous and mucous 
cells.  
2. In the floor of the mouth cavity: small sublingual and  
glossopalatine glands.  
     3. On the tongue: anterior lingual and posterior lingual glands 
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Composition of saliva  
 Saliva is a colourless opalescent viscous liquid. It consists of water, 
inorganic constituents of the extracellular fluid, and organic compounds, 
notably the protein enzymes and mucin.  
 Its composition shows a great variability in the concentration of the 
chief individual constituents. The ‘mixed’ saliva collected from the mouth 
is a mixture of the secretions of main and accessory glands and thus is not 
very constant in composition. Also it must be realized that the addition of 
bacterial products of fermentation and putrefaction, food debris, 
desquamated epithelial cells, and evolution of carbon dioxide into the 
atmosphere will further modify the composition of the saliva in the 
mouth.  
 The main cations of saliva are sodium, potassium, calcium and 
magnesium and the principal anions are chloride, bicarbonate with smaller 
concentrations of phosphate and sulphate and traces of thiocyanate, 
iodide, fluoride and nitrite. The levels of these ions may be influenced by 
gland of origin, age, sex, rate of secretion, nature of stimulus, plasma 
concentration, diet and disease.  
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 In general, distinctive characteristics of human saliva are its 
hypotonicity, and the lower sodium and higher potassium levels relative 
to the extracellular fluid concentrations. 
 
Organic constituents  
 The organic constituents of saliva include proteins, polypeptides, 
amnio acids, urea, uric acid, creatinine, cholesterol, citrate, thiocyanate; 
vitamins C and B complex. The proteins present are mainly mucin and 
amylase. In addition many other enzymes, group – specific agglutinogens, 
albumin, globulin, including blood clotting factors, have been 
demonstrated in saliva.  
 
Reaction of saliva  
 The reaction of saliva has been extensively studied both in health 
and disease. The reaction of saliva is markedly affected by flow rate, by 
the source of the saliva, and by the method of collection of saliva.  
 The human unstimulated mixed saliva as secreted is just on the acid 
side of neutrality. The mean pH is 6.7 with a range of from 5.6 to 7.6. 
Submandibular resting saliva has a slightly less acid reaction than parotid 
saliva.  
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 The pH of saliva is extremely sensitive to changes of flow rate. 
With increased flow in stimulated glands the pH rises and the salivary 
reaction approximates to the slightly alkaline reaction of plasma.  
        The cells of the duct system modify the acinar fluid to form the 
ultimate hypotonic saliva. This ductal activity includes in the main active 
reabsorption, active secretion and passive transport.   
The mechanism of formation of acinar fluid is essentially an active 
secretory process and not merely a physical process of ultra filtration. The 
acini are the main source of the water content of all saliva. Saliva contains 
substances, e.g. amylase and mucins, which are not present in plasma and 
are therefore synthesized in the gland cells.  
The saliva is the end result of the functional activity of several 
types of cell, particularly a) serous and mucous acinar cells b) striated 
intralobular duct epithelium c) cells of the main ducts. It is produced by 
acinar secretion, followed by active ductal reabsorption and secretory 
activity.  
 
Functions of saliva  
 Saliva fulfils a number of functions. These include moistening of 
the mouth, cleansing action, lubrication in swallowing and speech, 
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buffering, diluent and solvent action, digestive action, thirst mechanism 
and antibacterial activity.  
   
Innervations of salivary glands  
 The major salivary glands have a double autonomic supply from 
the parasympathetic and sympathetic divisions of the autonomic nervous 
system.  
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AETIOLOGY OF ORAL AND OROPHARYNGEAL 
CANCER 
Predisposing Factors  
Treatment of cancers of the head and neck requires an understanding 
of their etiology and development. Although the exact cause of these 
cancers is unknown there is evidence to suggest that they may result from 
repeated damage to the mucosa by one or more of the factors reviewed 
below.  
 
1. Smoking tobacco: 
The risk of malignancy is 6 times greater for smokers.  In addition 
in South East Asia, beedis, hookah and reverse smoking are also 
practiced. The relationship between reverse smoking and palatal cancer 
has been noted.  The carcinogens in tobacco smoke are N-nitrosamines, 
polycyclic hydrocarbons and benzyl–pyrines.   
 
2.  Chewing Tobacco (smokeless Tobacco) or Betel nut:  
Oral cancer has been observed at the site of placement of the quid, 
which consists of tobacco, betel leaf, lime, areca nut and sweetening 
agents. The habit of chewing various forms of tobacco is widely 
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practiced in India.  The probable carcinogens are aracholic acid, slaked 
lime and tannic acid. 
3.  Alcohol: 
 This acts in various ways to cause malignancy. It may act directly as a 
carcinogen, indirectly by causing vitamin deficiency and alcoholic 
cirrhosis which prevents detoxification of potential carcinogens.  It also 
acts by altering the  metabolism of oral and oesophageal mucosal 
epithelium and thus facilitates the entry of carcinogens.  The risk of 
malignancy in a smoker who also drinks alcohol is fifteen times higher 
when compared to a person with neither habit.   
 4.  Syphilis: 
 The etiological role of syphilis was based on the seropositive reaction 
seen in patient with oral cancer, as well as the observation that patient 
with syphilis of the tongue developed malignancy.  
 
5.  Diet and Nutrition:  
 Factors associated with an increased risk of cancer are iron deficiency 
anaemia (Plummer – Vinson syndrome), Vitamins A and C deficiency, 
carotenoids. Dietary deficiency can cause epithelial atrophy which renders 
the epithelium vulnerable to the action of carcinogens. 
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6.  Orodental Factors  
 Poor oral hygiene, sharp teeth and ill fitting dentures are possible 
etiological factors and seen mostly over the lateral border of the tongue 
and the cheek mucosa.  
7.  Solar Exposure: 
  The lip is susceptible to mucosal changes due to the absence of 
melanin pigment which acts as protection against u-v radiation.  The ultra 
violet radiation is especially damaging to the vermilion border of the 
lower lip.  
8. Viral Causes: 
Human papilloma virus is capable of transforming cells to a 
malignant phenotype. HSV–I (herpes simplex virus) and HIV(human 
immunodeficiency virus) have also been suggested in the pathogenesis of 
oral squamous cell carcinomas.  
9. Genetic: 
Mutations in the tumour suppressor genes have been found to be 
responsible for malignant transformation of tissues. The most commonly 
identified mutations is in the tumour suppressor gene p53 located on 
chromosome 17.  It plays an important role in the regulation of cell 
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proliferation. This gene is a potential tumour marker for the future. The 
epidermal growth factor receptor gene (EGF-R), an oncogene has been 
associated with squamous cell carcinoma of the head and neck.  
Nitrosamines can deregulate p53 and oncogenes leading to neoplastic 
alteration.  
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PATHOPHYSIOLOGY 
Carcinogenesis:  
  Various substances organic/inorganic, radiation, viral agents, etc. 
are found to be responsible for carcinogenesis.  Of all these smoking and 
alcohol are the two most important causes for the development of 
malignancy.   
 It is found that processed unadulterated tobacco contains at least 
2550 known compounds, of which at least 25 compounds are found to be 
associated with malignancy in humans.  
Various theories have been put forth to explain the development of 
cancer, of which four important theories are.  
 
1. Electrophilicity of chemicals as a determinant of their 
carcinogenicity.  It is proposed that most carcinogens could be 
considered as pro-carcinogens which change to carcinogens by 
chemicals due to their electrophilicity and ultimately result in 
cancer.   
2. Free radicals could be responsible in the formation of carcinomas 
or act as carcinogens themselves and lead to cancer.   
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3. Carcinogens which cause alteration of DNA methylation and thus 
result in cancer.   
4. Aberrations of DNA repair, wherein carcinogens affect DNA 
repair, and thus result in cancer.  
 
Stages: 
Biological characteristics  of the stages in Carcinogenesis   
a) Initiation: Irreversible  
With constant ‘stem cell potential’ by a mutagen or mutation.   
Efficacy is sensitive to xenobiotic and other chemical factors.   
Spontaneous occurrence of initiated cells can be demonstrated.  
Requires cell division for ‘fixation’  
Dose response does not exhibit a readily measurable threshold  
Relative effect of initiators depends on the quantization of focal 
lesions following a definite period of promotion. 
   
b) Promotion: Reversible 
Promoted cell population existence is dependent on continued      
administration of the promoting agent.          
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Efficacy is sensitive to dietary and hormonal factors. Dose response 
exhibits a readily measurable threshold and the maximal effect is 
dependent on the dose of the initiating agent.   
Relative effectiveness of promoters depends on their ability with 
constant exposure to cause an expansion of the progeny of the initiated 
cell population.  
 
c) Progression: Irreversible  
Measurable and/or morphologically discernible alteration in cell 
genome structure.  
Growth of altered cells is sensitive to environmental factors during the 
early phase.   
Benign and/or malignant neoplasms are characteristically seen  
 “Progressor” agents act to advance promoted cells into this stage but 
may     not be initiating agents. 
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Spontaneous progression can be demonstrated. 
 
Irrespective of the cause, ultimately malignancy is resulted from 
subversion of the processes that control the normal growth, location and 
mortality of cells.  This loss of normal control mechanisms arises from the 
acquisition of mutations in three broad categories of genes.  
 
1. Proto–Oncogenes:  
The normal products which are components of signaling pathways 
that regulate proliferations and which in their mutated form become the 
dominant oncogene. This may be by mutation or DNA rearrangement or 
gene amplification due to the action of chemicals, radiation or viruses 
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2. DNA repair enzymes:  
Mutations in DNA repair enzymes promote genetic instability due 
to faulty or absent regulation of damaged nuclear material.  
 
3. Tumour suppressor genes: 
Which generally exhibit recessive behaviour, the loss of function of 
which leads to deregulated control of the cell cycle progression, cellular 
adhesion etc.  Nearly 50 of such kind are identified of which p53 is most 
important.  
 p53: It is a normal transcriptional factor.  
(i) It regulates the normal cell growth cycle by activating transcription 
of genes that control progressions through the cycle and of other genes 
that cause arrest in ‘G1’ phase when the genome is damaged and in 
some cell types promote apoptosis.  
Hypoxia occurring in areas of tumours with poor blood supply 
promotes p53      dependent apoptosis, cells with mutated p53 are resistant 
to killing by hypoxia. 
(ii) It also possesses 3 to 5 DNA exonuclease capacity. This 
Magnesium dependent activity may be involved in replication 
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associated DNA repair, p53 acting as a proof reading enzyme for DNA 
polymerases.  
Mutations in the single copy P53 gene are the most frequent genetic 
changes, shown to be associated with human cancers and point mutations. 
Deletions or insertions in p53 occur in nearly 70% of all malignant 
tumours.  
                      
Salivary antioxidant system 
Saliva is the first biological medium met by external materials 
taken into the body as part of food, drink, or inhaled volatile ingredients. 
During evolution, various defense mechanisms developed in the saliva 
aimed at combating penetrating bacteria, viruses or fungi, and protecting 
against chemical or mechanical attack. Moreover, even after swallowing, 
saliva has a mucosal protective capacity within the gastrointestinal tract . 
An extensive amount of research has been devoted to the immunologic 
defense mechanism of saliva, primarily based on secretory 
immunoglobulin A and the protein-enzymatic defense system. That, in 
turn, is based on the enzyme lysozyme and other components, such as 
histatin, lactoferrin, proline-rich protein, mucin, etc. The soft tissue 
integrity defense system, in which the epidermal growth factor plays a 
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pivotal role, has also been evaluated thoroughly. Recently, the importance 
of an additional salivary defense system has become clear i.e the 
antioxidant defence system. Similar to other biological systems, the 
salivary antioxidant system includes various molecules and enzymes, the 
most important of which are the uric acid molecule the antioxidant 
defense system, which appears to lose efficiency with advanced age and 
the peroxidase enzyme, both of them water-soluble. The lipid-soluble 
antioxidants carried by lipoproteins, whose concentration in saliva is very 
low, contribute no more than 10% of the total salivary antioxidant 
capacity. Uric acid, the most important antioxidant molecule in saliva 
contributes approximately 70% of the total salivary antioxidant capacity, 
with the antioxidant role of the ascorbic acid molecule being secondary   
 
Saliva- as a diagnostic sample 
Saliva is ultrafiltrate of plasma. In a clinic or lab, saliva is relatively 
easy to collect in sufficient quantities for analysis and the costs of storage 
and shipping tend to be lower than those for serum and urine. Saliva is 
easy to obtain, with less invasion of privacy and ease of adulteration, 
compared to urine. Salivary sampling protocols are advantageous as they 
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make for frequent and easy collection of samples by non-invasive 
NEEDLE-FREE stress free techniques. 
Advantages: 
Saliva measures free, bioavailable fraction of steroid hormones and 
drug that have moved out of bloodstream and into the tissue. 
• Most reliable measurement of tissue uptake in case of topical hormone 
supplement. 
• Painless, non-invasive, needle free. 
• Private, convenient for both patient and doctor. 
• Transportation of saliva samples to laboratory requires no special 
handling. 
• Less expensive than conventional blood testing. 
• Ease of collection allows for routine monitoring and adjustment of 
hormone supplement if required. 
 
Clinical presentation and diagnosis 
Malignancies arising from the mucosa of the oral cavity are epithelial 
in origin and are therefore, classified as squamous cell carcinomas more 
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than 90% of the time. According to the degree of differentiation, three 
subtypes are defined:  
1. well-differentiated squamous cell carcinoma showing more than 
75% keratinization 
2. Moderately differentiated squamous cell carcinoma with 25-75% 
keratinization 
3. Poorly differentiated squamous cell carcinoma with less than 25% 
keratinization 
The majority of cases are of moderate differentiation. A clear relationship 
between 
histological differentiation and clinical prognosis has not been 
established, although a lack of differentiation has been associated with 
more rapid growth and spread. The morphologic classification of 
squamous cell carcinoma by degree of differentiation is used in the 
description of the histopathological specimen. 
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The presentations of oral cancers will be: 
• Ulcer 
• Growth 
• Patches or plaques 
• Bleeding 
• Halitosis 
• Dysphagia or odynophagia 
• Pain in mouth or ear 
• Neck swellings (lymph nodes) 
• Orocutaneous fistulae 
The diagnosis of oral cancers is mainly by clinical examination. Tissue 
biopsy confirmation is done by Edge-wedge biopsy. Other investigations 
– chest X-ray, CT scan, MRI scan- are done to stage the disease and 
assess the operability status. 
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STAGING 
The staging of oral cancers is done by TNM staging system, where 
T denotes Tumor, N stands for Nodal metastases and M for Distal 
metastases. 
 
TX  Primary  tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ 
T1  Tumor 2 cm or less in greatest dimension 
T2  Tumor more than 2 cm but not more than 4 cm in greatest 
dimension 
T3  Tumor more than 4 cm in greatest dimension.  
T4a (Lip)- Tumor invades through cortical bone, inferior alveolar nerve, 
floor of mouth, or skin of face (ie, chin or nose) 
(Oral Cavity)- Tumor invades through cortical bone, into deep 
extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and 
styloglossus), maxillary sinus, or skin of face 
T4b  Tumor involves masticator space, pterygoid plates, or skull base 
and/or encases internal carotid artery 
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NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in a single ipsilateral lymph node, 3 cm or less in 
greatest dimension 
N2  Metastasis in a single ipsilateral lymph node, more than 3 cm but 
not more than 6 cm in greatest dimension; in multiple ipsilateral lymph 
nodes, none more than 6 cm in greatest dimension; in bilateral or 
contralateral lymph nodes, none more than 6 cm in greatest dimension 
N2a  Metastasis in single ipsilateral lymph node more than 3 cm but not 
more than 6 cm in greatest dimension 
N2b  Metastasis in multiple ipsilateral lymph nodes, none more than 6 
cm in greatest dimension 
N2c  Metastasis in bilateral or contralateral lymph nodes, none more than 
6 cm in greatest dimension 
N3  Metastasis in a lymph node more than 6 cm in greatest dimension 
MX  Presence of distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
Treatment  
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The treatment of oral cancers depends on site, stage of the tumor 
apart from patient factors. Methods available for the treatment include- 
Surgery, Radiotherapy, Chemotherapy.. 
Surgery and radiation therapy are the only curative treatments for 
carcinoma arising in the head and neck. Chemotherapy is useful in the 
adjuvant setting; used alone, it is not curative. 
The advantages of an operation compared with radiation therapy, 
assuming similar cure rates, may include the following: (1) a limited 
amount of tissue is exposed to treatment, (2) treatment time is shorter, (3) 
the risk of immediate and late radiation sequelae is avoided, and (4) 
irradiation is reserved for a subsequent head and neck primary tumor, 
which may not be as suitable for an operation. 
The advantages of irradiation may include the following: (1) the 
risk of a major postoperative complication is avoided, (2) no tissues are 
removed so that the probability of a functional or cosmetic defect may be 
reduced, (3) elective irradiation of the lymph nodes can be included with 
little added morbidity, whereas the surgeon must either observe the neck 
or proceed with an elective neck dissection (sometimes bilateral 
depending on the primary site), and (4) the surgical salvage of irradiation 
failure is probably more likely than the salvage of a surgical failure. 
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Wide local excision, composite resection with neck dissection are the 
common surgical procedures followed 
Rescue of a surgical failure may be attempted by operation, 
radiation therapy, or both. Surgical recurrences usually develop at the 
margins of the resection, in or near the suture line. It is difficult to 
distinguish the normal surgical scarring from recurrent disease, and 
diagnosis of recurrence is often delayed. Tumor response to radiation 
therapy under these circumstances is poor. An operation, radiation 
therapy, or both, however, may salvage small mucosal recurrences and 
some neck recurrences. 
Indications for postoperative radiation therapy include close (less 
than 5-mm) or positive margins, extracapsular extension, multiple positive 
nodes, invasion of the soft tissues of the neck, endothelial-lined space 
invasion, perineural invasion, and more than 5 mm of subglottic invasion. 
Chemotherapy may be administered to palliate symptoms in patients with 
incurable head and neck cancer or as an adjuvant to radiation therapy or 
surgery, or both, to improve the probability of cure. Adjuvant 
chemotherapy may be administered before definitive treatment 
(induction), simultaneously with radiation therapy (concomitant), or after 
radiation therapy or surgery (maintenance). 
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AIMS 
• To identify a novel Bio-marker in oral cancers using saliva 
• To study the relationship between smoking and oral cancers 
• To study the different modes of presentation of oral cancers 
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MATERIALS AND METHODS 
Sample collection: 
Parafilm (2”X2”)  
Gloves and Mask 
Short stem plastic funnels (Disposable) 
Storage vials 
Ice packs and  
Labels and marker pens 
Sample Processing: 
Bradford’s Protein Quantification 
SDS : PAGE 
Coomassie staining of SDS PAGE 
Silver staining 
Colloidal coomassie brilliant blue staining 
All the patient samples included in the screening analysis study 
were collected from Government Rajaji Hospital, Madurai, India. A total 
of 155 samples were collected which includes 82control (Healthy 
individuals), 39 from patients with oral cancer due to smoking and 34 due 
to non-smoking.  
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Stimulated whole saliva was collected with modified protocol of 
Navazash, 1993, which includes the following steps: 
1. Individuals were abstained from eating, drinking, smoking or 
brushing their teeth for at least 60 min prior to collection. 
2. To swallow or discard any accumulated saliva 
3. Place a standard piece of parafilm in the mouth and chewed on at a 
regular pace 
4. To expectorate saliva periodically into a collection storage vial 
(10ml).  The volume and physical characteristics of the specimens 
were recorded. Approximately 5ml of sample were obtained from 
each individual (Ohshiro et al., 2007). 
5. Dispose the funnels and parafilm after use. Cap the collection vials 
and let stand approximately one hour or until and saliva and foam 
have settled, which may require shaking.  Temporary I.D. were 
created on tubes with permanent I.D. labels, one the sample 
collection is finished. Place samples in -20 0C freezer for storage or 
in the refrigerator. 
6. The samples were transported to research area using ice pack 
coolants. 
 43
 
 
 
Sample Processing 
Vials were thawed and centrifuged at 3000 rpm for 5-10 minutes 
and supernatant was collected and cocktail protease inhibitor was 
added for protein degradation minimization.  The supernatant fractions 
were stored in 250µl aliquots in -20 0C until analysis. (Modified 
protocol of Balwant, 2007).    
 
Bradford’s protein quantification  
 
Bradford’s Reagent  
Dissolve 100mg of G-250 in 100ml of absolute/ distilled ethanol or 
absolute methanol in on a shaker for 60 min. Add 100ml  88% 
orthophosphoric acid, mix well and make the volume to 500ml with 
distilled water. Filter through Whatman No. 1.  Dilute 1:1 with water and 
check the A550 against a water blank. The A550 should be approximately 
1.1.  If not adjust the dilution. 
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Procedure 
Colorimetric Estimation 
1. Pipette out increasing amounts(10-100µl) of BSA stock solution 
(0.2 mg/ml) into clean dry test tubes.  
2. Make up the volume to 0.5ml with distilled water.  Keep a blank. 
3. Simultaneously the saliva samples were added (10-100µl) and 
made the volume to 0.5ml with distilled water. 
4. Add 4.5ml of the dye reagent and mix gently. 
5. Read the absorbency at 595 nm after 5 min at room temperature. 
6. The concentration of the protein was quantified by plotting optical 
density value against the BSA standard.  
 
SDS-PAGE 
Separating gel (10%) for 10ml 
30 % Acrylamide:Bis (29.2:0.8) - 3.3ml 
Tris-Hcl pH 8.8 (1.5M) -2.5ml 
SDS(10%)- 0.1ml 
De-ionised water  4.0 ml 
Ammonium persulphate (10%) – 0.1ml 
Finally TEMED   0.004 ml  
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Procedure 
Proteins were resolved in SDS-Polyacrylamide gel as described by 
Ausubel et al., 1989. routinely, 1.5 mm thick gels were cast using a 
separating gel (10%) and a stacking gel (5%).  The separating gel solution 
was first poured into a sealed glass plate cassette.  Water saturated n-
butanol was layered on top of the separating el and the gel was set to 
polymerize for 30 min at room temperature.  After polymerisation the 
butanol layer was removed carefully and the exposed end was rinsed with 
0.1% SDS. Stacking gel solution was poured onto the separating gel up to 
the cassette leaving 1cm. comb was inserted into the cassette leaving 1cm 
distance between the bottom of the slots and top of the separating gel.  
After the polymerization of the stacking gel, the comb was carefully 
removed. The slots were cleaned by rinsing with 1X TGS buffer.  The 
samples were heated in a boiling water bath for 3min, loaded into the slots 
and the slots were filled with 1XTGS buffer and a constant current of 21 
mA/ gel was applied. 
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Coomassie staining of SDS-PAGE  
 
After the completion of electrophoresis, the gel cassette was 
dismantled and the gel was immersed in coomassie blue staining solution 
and agitated slowly for 2hour. The gel was then left in destaining solution 
for 2 to 4 hours with 2 to 3 changes of the solution. After destaining, the 
gels were stored in 7% acetic acid. 
 
Silver staining 
Reagents  
1. fixing solution: 40% ethanol +10 acetic acid 
2. Rinsing solution: 30% ethanol 
3. Sensitizing solution: 0.02% sodium thiosulfate 
4. Staining solution: 0.1% silver nitrate 
5. Developing solution: 6% sodium carbonate+ 0.04 formalin (add just       
before the use from stock 40% or 37%) 
6. Stopper solution:  5% acetic acid 
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Procedure 
The gel was placed in fixing solution and gently shaked for 1 hr in 
a rotary shaker.  After incubation, the fixing solution were removed 
without touching the gel and rinsed with 30% alcohol for 20 min with 
gentle shaking,  washed thrice in water at each 10 min and sensitizing 
solution was added and left it from 1min.  Again the gel was washed 
thrice in water at each 30 seconds intervals.  The gel was stained by 
adding pre-cooled staining solution with gentle shaking in cold room for 
30 min, washed with water(10 seconds) and developed in a developing 
solution(fresh developer and gentle shaking until the protein/ peptide 
spots appeared clearly.  The gel was washed with water thrice for 10min 
and stored in 1% acetic acid. 
 
Colloidal coomassie brilliant blue staining 
 
Reagents: 
Solution I :  The solution I consisted of 16 ml of orthophosphoric acid, 
868 ml of distilled water and 800 gm of ammonium sulphate and they 
were mixed well 
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Solution II : The solution II was prepared with 5%  
CBB G250in distilled water and 16ml of solution I just prior to use. 
 
Solution III:  The solution III was prepared freshly by slowly adding 
200ml of methanol to the solution II to give a final concentration of 
0.08%            CBB G250, 1.6 % orthophosphoric acid, 8% ammonium 
sulphate and 20% methanol.  All solutions were prepared on a rotary 
shaker with gentle shaking. 
Procedure 
 
Solution III was poured in a plastic tray and the gel was placed and 
incubated for overnight with gentle shaking in a rotary shaker. 
 
Destaining  
Overnight stained gel was destained with several washes with double 
distilled water until the background get transparent. 
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RESULTS AND DISCUSSION 
 
Sample collection: 
 
Type of sample  No. of Samples Age groups(range) remarks 
Control 82 25-70 years ----- 
Smoker oral cancer 34 33-67 years Poor oral hygiene 
Non smoker oral 
cancer 
32 50- 65 years Poor oral hygiene 
Oral cancer without 
any habit 
7 45-55 years Poor oral hygiene 
 
Whole stimulated saliva were collected from the individuals of 4 
different category, to make a comparative study among them.  From the 
Above Table  it is found that the individual are more prone to oral cancer 
are due to poor oral hygiene which is found to be the main reason as the 
individuals with the habit of smoking or chewing tobacco are also found 
to have oral cancer.  While considering the occurrence of cancer with age, 
it is found that the age group ranges from 33 to 67 years. While, the age 
group ranging from the 55 to 65 are more susceptible for oral cancer.  
 
The secretion of saliva volume differs for individual to individual, 
so we used acid candies for collection of saliva samples. 
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SDS-  
A comparative study was made to check the protein profile using 
Sodium dodecyl sulfate - polyacrylamide gel electrophoresis.  The stored 
stimulated whole saliva was quantified and denatured.  250 µg of protein 
sample was loaded to SDS-PAGE gel for separation and the gel was 
stained with coomassie stain for visualization of protein bands, and 
documented in Alpha Imager 1200.   
The protocol was standardized as the proteins in the samples were 
degraded and were unable to perform the protein studies.  So, we started 
using cocktail protease inhibitor to avoid the problem of degradation 
(Fig1). 
Fig 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Fresh and stored saliva samples from different Normal (control) individuals 
were subjected to 12%SDS-PAGE and visualized via Coomassie blue staining. lanes 
A- marker, M-Male, F-Female, S-Stored sample(80µl), Fresh sample F&M- 50µl
   M        1        2       3        4       5         6       7  
205 KDa 
 
97.4KDa 
66 KDa 
 
43KDa 
 
29KDa 
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As the samples collected included the male and female, so SDS-PAGE 
was performed to compare the protein finger printing of the male and 
female sample and found to have similar pattern of protein banding(Fig 
2). 
 
 
Fig. 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral cancer whole saliva samples were screened to study the protein 
profile of oral cancer smokers sample in comparison to control samples. 
From the study, we found that the expression of protein level were found 
to be different in each sample Fig. 3 & Fig. 4 when compared to the 
control samples. Some of the proteins in the samples are found to be over 
expressed, which reveals that a particular protein cannot be chosen  based 
on the SDS-PAGE for identification of Oral Cancer Biomarker. 
Fig.2 Test saliva sample were subjected to 12%SDS-PAGE and visualized via Coomassie blue 
staining. Lanes M- Molecular  weight marker, Lanes 1-5 oral cancer-smoker saliva sample, C- 
Healthy control. Sample- 80µl (80µg) 
   M        1        2       3        4       5         6       7  
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Fig 3 
 
 
Fig 4 
 
 
 
 
 
 
 
 205KDa 
  
  97.4 KDa 
  66KDa 
  
 43KDa 
    
 29KDa 
 
M 1 2 3 4 5 C
6 7 8 9 10 M
Fig.3 & 4. Oral cancer saliva sample were subjected to 12%SDS-PAGE and visualized 
via coomassie blue staining Lanes M-Molecular weight marker, Lanes 6-10 oral cancer-
smoker sample, C-Healthy control 
 205KDa 
  
  97.4 KDa 
  66KDa 
  
 43KDa 
   
  
 29KDa 
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Simultaneously the SDS-PAGE analysis was performed in 12% gel 
to check whether the pattern of the protein banding is similar in oral 
cancer smokers sample to that of non-smokers oral cancer sample. As a 
result we found the protein expression of the samples of oral cancer non-
smokers and the oral cancer without any habit were found to be under 
expressed when loaded the same amount of quantified whole saliva 
protein. (Fig.5) 
 
  
 
Fig 5 
 
 
 
 
 
 
 
 
205 KDa 
 
97.4KDa 
 
66 KDa 
 
43KDa 
 
29KDa 
M F1 M1 F2 F3 F4 C
Fig.5 Non-smoker test saliva sample were subjected to 12%SDS-PAGE and visualized via 
coomassie blue staining. Lanes M-Molecular weight marker, Lanes 6-10 oral cancer-
nonsmoker sample, C-Healthy control 
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Further, Two Dimensional Electrophoresis (2DE)  was performed as a 
attempt to know the complete proteome profile. We performed 2DE 
which include the first dimension of  Isoelectric Focusing at a pH range of 
3-10, 11CM pH strip which was followed by the second dimension of  
12.5% separating PAGE gel and the silver stained or colloidal coomassie 
stained to visualize the protein spots. 250 µg of  quantified protein sample 
using Bradford’s method and found the proteins were visible only the pH 
range of 4-8. 
 
 
 
 
 pH 10                                                3 
Fig.6 Two-dimensional gel electrophoresis of salivary glandular secretions by isoelectric focusing with 
pH range 3-10 in the horizontal dimension. Proteins from control(100µg). gel was silver stained.  
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CONCLUSIONS 
1. The protein samples are highly degradable so the analysis should be 
done immediately after sample collection or cocktail protease 
inhibitor should be added to avoid degradation. 
2. Protein banding pattern of male and female control samples were 
similar in 12 % SDS-PAGE analysis.  
3. Over-expression level of proteins was found in smokers oral cancer 
patients when compared to control sample and also additional 
bands was found in three oral cancer sample, which shows that the 
expression level differs from individual to individual. 
4. The under expression of protein in female non-smokers oral cancer 
patient sample was found when compared to the control female and 
male smokers patient sample. 
5. 2DE protocol for whole saliva sample is performed which lies in 4-
8 pH range when the screened at 3-10 pH range. 
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FUTURE PLANS 
• Comparative proteome analysis of control and oral cancer saliva 
sample, using 2Dimensional Electrophoresis and MALDI-TOF/MS 
analysis at a pH range around 4 -8 pH has to be screened. 
 
When the target protein biomarker is identified, it can be used for 
diagnosis, prognostic or therapeutic purposes. 
65Yr MALE PATIENT WITH ULCEROPROLIFERATIVE 
GROWTH AT ® ANGLE OF MOUTH 
 
 
 
 
57Yr MALE PATIENT WITH ADVANCED CARCINOMA ® 
CHEEK WITH SKIN INVOLVEMENT 
(OROCUTANEOUS FISTULA) 
 
 
 
 
 
 
 
A 49Yr FEMALE PATIENT WITH ADVANCED 
CARCINOMA ® CHEEK WITH MANDIBULAR AND SKIN 
INVOLVEMENT  
 
 
 
 
A 51Yr MALE PATIENT MALIGNANT ULCERATIVE 
LESION IN ® CHEEK  
 
 
 
 
 
A 62Yr MALE PATIENT WITH 
ULCEROPROLIFERATIVE LESION OVER (L) LATERAL 
BORDER OF THE TONGUE 
 
 
A 58Yr MALE PATIENT WITH CARCINOMA LOWER LIP 
WITH BILATERAL LOWER LIP AND ALSO BILATERAL 
UPPER LIP INVOLVEMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 64Yr MALE PATIENT WITH 
ULCEROPROLIFERATIVE GROWTH IN FLOOR OF 
MOUTH ON (L) SIDE  
 
 
 
PROFORMA 
 
IDENTIFICATION  OF  NOVEL  BIOMARKER  FOR  ORAL  CANCER  USING SALIVA. 
 
 
 
Patient details                                                                  Sample no.:  
 
                                                                                           Date of admission:     
Name        : 
 
Age/sex     : 
 
I.P no/unit : 
 
Address     : 
 
 
 
 
 
Complaints: 
 
 
Significant history/ 
 comorbid conditions: 
 
Smoking: 
 
 
 
On exmn: 
 
Gross 
 
 
 
 
 
 
Microscopy 
 
Diagnosis: 
S.No Name Age Sex IP No.
Date of 
Admission Father/Husband Address Ward Comorbidity
Ulcer Growth Bleeding Pain Dysphagia Trismus Period (months) Type Period(years) Quantity/Day Alcoholic Beetel nut
1 VAYANA PERUMAL 65 MALE 100462 6/3/2008 ATHISAMY MADURAI SUR4  9  9 4  9 BEEDIES 25 4 TO 6
CARCINOMA LEFT LOWER 
GINGIVOBUCCAL SULCUS T3N1M0
2 SUBRAMANI 60 MALE 30130 13/3/2008 PALANI MADURAI ENT2  9  9  9 2  9 BEEDIES 25 20 TO 25
CARCINOMA LEFT LATERAL BORDER OF 
TONGUE T4N1M0
3 NALLA KAMAN 58 MALE 32998 13/3/2008 VEERATHEVAR MADURAI ENT1  9  9 1  9 BEEDIES 20 12TO15
CARCINOMA POSTERIOR 1/3RD OF 
TONGUE T2N1M0
4 VASANTHA 57 FEMALE 54784 22/6/2008 MANI MADURAI ENT2  9 6 DIABETES CARCINOMA LEFT TONSIL T4N2bM0
5 MURUGAN 33 MALE 11153 3/4/2008 SUBBIAH CHETTIAR TIRUNELVELI SUR4  9 3  9 BEEDIES 25 12TO15 CARCINOMARIGHT CHEEK T3N1M0
6 SUBRAMANI 68 MALE 39202 14/4/2008 NAGAPPA ARUPPUKOTAI S.ONCO  9  9 1  9 BEEDIES 10 5TO6  9  9 DIABETES
CARCINOMA TONGUE RIGHT 
SIDE(OPERATED‐POSITVE MARGINS)
7 SOLAIAPPAN 62 MALE 37502 15/4/2008 KALIAPPAN MADURAI ENT1  9  9 8  9 BEEDIES 10 10TO12 CARCINOMA RIGHT TONSIL T2N1M0
8 NAINA MOHAMMED 67 MALE 39664 15/4/2008 MD MEERAN SIVAGANGAI ENT2  9  9 6  9 BEEDIES 25 25TO30  9 CACINOMA OROPHARYNX RIGHT SIDE T4N1M0
9 SEKAR 55 MALE 52169 20/6/2008 PERUMALSAMY SIVAKASI SUR4  9 3  9 BEEDIES 20 25TO30  9 HYPERTENSION CARCINOMA RIGHT VALLECULA T4N2bM0
10 CHINNAVELUSAMY 65 MALE 53685 22/6/2008 PERIYASAMY MADURAI ENT2  9 4  9 BEEDIES 30 30TO32 CARCINOMA LEFT TONSIL T3N2M0
11 THIRUMALASAMY 73 MALE 59072 14/7/2008 GOPALSAMY THENI S.ONCO  9 6  9 CIGARETTES 10 3TO5
CARCINOMA LEFT HARD PALATE WITH 
MELANOPLAKIA T2N0M0
12 PALANISAMY 62 MALE 59900 5/7/2008 KARUPPIAH MADURAI S.ONCO  9 6  9 BEEDIES 40 15TO20 ?TVGJ done
CARCINOMA LEFT CHEEK BUCCAL 
MUCOSA T3N0M0
13 ALLIS 56 FEMALE 28764 11/3/2008 SABISTON MOONAR SUR6  9  9 12  9 
CARCINOMA LEFT CHEEK BUCCAL 
MUCOSA T3N1M0
14 MARIMUTHU 63 FEMALE 29065 19/3/2008 VELLPPAMUPANAR THENI SUR1  9  9 12  9 
CARCINOMA RIGHT CHEEK  BUCCAL 
MUCOSA T4aN2cM0
15 CHITTAL 54 FEMALE 37273 31/3/2008 ADAIKAN PUDUKOTAI SUR7  9  9  9 60  9 CARCINOMA LEFT  LOWER ALVEOLUS T4bN2cM0
16 PAPPA 65 FEMALE 34370 31/3/2008 AIYYAR NILAIKOTAI SUR5  9  9 6  9 
CARCINOMA LEFT CHEEK BUCCAL 
MUCOSA T4N1M0
17 MARIAPPAN 60 MALE 35128 12/4/2008 PALANIJOTHI THENI S.ONCO  9 2  9 BEEDIES 30 20TO25  9 CARCINOMA LEFT BONY ALVEOLUS T4aN1M0
18 PITCHAIMMAL 50 FEMALE 39658 12/4/2008 MANI MADURAI S.ONCO  9 3 CARCINOMA  TONGUE LEFT SIDE T2/3N2M0
19 SONAI MUTHU 55 MALE 33384 13/3/2008 SIVALINGAM SIVAKASI  9  9 4  9 BEEDIES 20 15TO18  9 CARCINOMA LEFT OROPHARYNX T2N1M0
20 MUTHIAH 47 MALE 60013 14/7/2008 NALLAN DINDIGUL S.ONCO  9 6  9 CARCINOMA RIGHT SIDE TONGUE T2N2bM0
21 VELUTHAI 60 FEMALE 59816 14/7/2008 VELLAIYAN DINDIGUL S.ONCO  9  9 10  9 CARCINOMA LEFT BUCCAL MUCOSA T1N0M0
22 PONNUSAMY 50 MALE 39834 15/4/2008 SAMIKANNUSERVAI MADURAI ENT1  9 4  9 BEEDIES 30 15TO20  9 TUBERCULOSIS
CARCINOMA RIGHT POSTERIOR 1/3RD 
TONGUE T2N1M0
23 CHANDIRAMANI 55 MALE 47005 22/6/2008 JACOB NAGERCOIL ENT2  9 6  9 BEEDIES 40 7PACKS  9 
CARCINOMA LEFT POSTERIOR 1/3RD 
TONGUE T4N2bM0
24 PALANIYAMMAL 50 FEMALE 79965 28/9/2008 NAGAMUTHU DINDIGUL S.ONCO  9  9 4  9 MITRAL STENOSIS CARCINOMA  LEFT LOWER ALVEOLUS T4N2MO
25 RAMAYEE 50 FEMALE 80631 29/8/2008 RAMASAMY DINDIGUL S.ONCO  9  9  9  9 3  9 CARCINOMA FLOOR OF MOUTH T4N1M0
26 ELIZABETH 65 FEMALE 80019 28/9/2008 MICHAEL VIRUDHANAGAR S.ONCO  9 4  9 
CARCINOMA LEFT BUCCAL MUCOSA, 
RETROMOLAR TRIGONE T4N1M0
27 MARIAPPAN 65 MALE 35128 18/3/2008 PALANIJOTHI THENI S.ONCO   9    9  6   9  BEEDIES 20 5PACKS   9  CARCINOMA LEFT UPPER ALVEOLUS T4N2M0
28 KATHAYEE 50 FEMALE 38216 3/4/2008 ALAGAR MADURAI SUR7   9    9  5
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T2N1M0
29 SUBRAMANI 68 MALE 39202 8/4/2008 RAIKAPPAN VIRUDHANAGAR S.ONCO   9    9  3   9  CARCINOMA TONGUE LEFT SIDE T2N0M0
30 PITCHAIMANI 50 FEMALE 39658 10/4/2008 MANI MADURAI S.ONCO   9  8   9  CIGARETTES 20 5TO8 CARCINOMA TONGUE RIGHT SIDE  T2N1M0
31 LAKSHMANAN 67 MALE 39689 10/4/2008 RAJAGOPAL MADURAI S.ONCO   9  6   9  BEEDIES 23 15TO20   9    9  DIABETES CARCINOMA TONGUE LEFT SIDE T3N2bM0
32 CHINNAIAH 65 MALE 40737 15/4/2008 MANKABAKAN DINDIGUL S.ONCO   9  6   9  BEEDIES 15 15TO20   9  CARCINOMA LEFT UPPER ALVEOLUS T4N2cM0
33 KARUPPANAN 40 MALE 41179 17/4/2008 VELLAIKANNU SIVAGANGAI ENT2   9  6   9  CIGARETTES 15 10TO12   9  CARCINOMA PAROTID RIGHT SIDE T2N1M0
34 ABDUL KHADER 65 MALE 43633 29/4/2008 SULAIMAN DINDIGUL ENT2   9    9  6   9  BEEDIES 25 18TO20 CARCINOMA RIGHT UPPER ALVEOLUS T3N2bM0
35 VEERAMMAL 50 FEMALE 44067 1/5/2008 ALAGAR DINDIGUL S.ONCO   9    9  4   9  
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T2N1M0
36 INDRAMMAL 70 FEMALE 44093 1/5/2008 PALANICHAMY THENI S.ONCO   9    9  5 CARCINOMA TONGUE LEFT SIDE T2N1M0
Complaints Smoking DiagnosisOthers
37 GANESAN 29 MALE 45311 7/5/2008 AIYANAR MADURAI SUR7   9  3   9  BEEDIES 10 20TO30 CARCINOMA TONGUE LEFT SIDE T3N2bM0
38 ANNAMALAI 30 MALE 49549 27/5/2008 VELUSAMY TANJORE S.ONCO   9  5   9  BEEDIES 26 15TO20   9    9  
CARCINOMA POSTERIOR 1/3RD OF 
TONGUE T4N2cM0
39 RAKKIAH 58 MALE 50045 29/5/2008 RAMASAMY ANDIPATTI S.ONCO   9  2
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T3N1M0
40 KOKILA 50 FEMALE 500905 3/6/2008 KUMAR VIRUDHANAGAR S.ONCO   9    9  6 CARCINOMA HARD PALATE LEFT SIDE T4bN2cM0
41 RAJKUMAR 55 MALE 51382 11/6/2008 RAMASAMY ANDIPATTI S.ONCO   9    9    9    9  6   9  BEEDIES 29 20TO22 DIABETES, HYPERTEN
CARCINOMA BUCCAL MUCOSA RIGHT 
SIDE T3N2bM0
42 KUMAR 47 MALE 521166 9/6/2008 SEVUGAN MADURAI S.ONCO   9  1   9  CIGARETTES 14 10TO12   9  DIABETES CARCINOMA OROPHARYNX T4bN2cM0
43 PANDIAMMAAL 63 FEMALE 54539 19/6/2008 ARMUGAM SELLUR S.ONCO   9  18   9  CARCINOMA LEFT UPPER ALVEOLUS T4bN2cM0
44 PITCHAI 67 MALE 53293 24/6/2008 CHIDAMBARAM MADURAI S.ONCO   9    9  7   9  
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T3N1M0
45 PANDIARAJAN 57 MALE 57639 1/7/2008 MAYANDIPILLAI MADURAI S.ONCO   9  5   9  BEEDIES 15 15TO20
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T3N2bM0
46 LAKSHMI 53 FEMALE 58449 4/7/2008 KARUPPAIAH MADURAI S.ONCO   9    9    9    9  10 CARCINOMA LIP LEFT LOWER SIDE T2N1M0
47 MUTHIAH 42 MALE 60013 12/7/2008 SAILAR DINDIGUL S.ONCO   9  9   9  CARCINOMA TONGUE RIGHT SIDE T2N1M0
48 PALANISAMY 47 MALE 60031 10/7/2008 ALAGARSAMY DINDIGUL S.ONCO   9    9  3   9  BEEDIES 20 20TO22   9  HYPERTENSION CARCINOMA LEFT UPPER ALVEOLUS T3N2aM0
49 RAMAKRISHNAN 56 MALE 61316 15/7/2008 GANAPATHY VIRUDHANAGAR S.ONCO   9  24   9  CARCINOMA PAROTID LEFT SIDE T3N1M0
50 BALAKRISHNAN 55 MALE 64276 26/7/2008 NELLAIANANTHAN MADURAI ENT1   9  8   9  BEEDIES 25 3PACKS   9  CARCINOMA TONGUE LEFT SIDE T2N0M0
51 MEENATCHI 70 FEMALE 64892 29/7/2008 ZAKIR SELLUR ENT1   9  3   9  CARCINOMA RIGHT LOWER ALVEOLUS T2N2aM0
52 SOLAIAPPAN 70 MALE 74797 4/9/2008 SOLAI MADURAI SUR5   9  7   9  BEEDIES 25 1PACK   9  CARCINOMA TONGUE RIGHT SIDE T2N1M0
53 ALAGAMMAL 60 FEMALE 80027 23/9/2008 PARAMAN MELUR SUR3   9    9  5 CARCINOMA RIGHT UPPER ALVEOLUS T3N2cM0
54 ARMUGAM 52 MALE 80639 25/9/2008 SANNASI MADURAI S.ONCO   9  1   9  BEEDIES 23 12TO15 DIABETES
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T2N2bM0
55 LATCHMIAMMAL 65 FEMALE 80652 25/9/2008 ALAGARSAMY KARIYAPATTI S.ONCO   9  5   9  CARCINOMA LEFT LOWER ALVEOLUS T2N2bM0
56 PONNUTHAI 60 FEMALE 82124 30/9/2008 SUNDARAM MADURAI ENT2   9    9     9  CARCINOMA LEFT UPPER ALVEOLUS T4aN2cM0
57 BALAMURUGAN 51 MALE 98903 16/12/2008 VAIRAVALAL DINDIGUL S.ONCO   9  18   9    9  CARCINOMA PAROTID LEFT SIDE T3N1M0
58 BOOPATHI 55 MALE 99788 24/12/2008 GANDHICHETTIAR THENI S.ONCO   9    9  1   9  BEEDIES 30 4PACK   9  LEFT SUBMANDIBULAR GLAND TUMOR T2N1M0
59 AMMAL 48 FEMALE 7534 29/1/2009 RAJI THENI S.ONCO   9    9    9    9  4
CARCINOMA BUCCAL MUCOSA LEFT 
SIDE T2N2bM0
60 KAMATCHIAMMAL 75 FEMALE 7568 29/1/2009 PANJARU NAIDU THENI S.ONCO   9  6   9  
CARCINOMA BUCCAL MUCOSA RIGHT 
SIDE T2N1M0
61 MADHAVAN 60 MALE 26177 2/3/2009 SHANMUGAM SIVAGANGAI S.ONCO   9  3   9  CIGARETTES 10 8TO10 CARCINOMA TONGUE LEFT SIDE T2N1M0
62 MOORTHI 55 MALE 30764 20/3/2009 GANDHI THENI S.ONCO   9  10   9    9  LEFT SUBMANDIBULAR GLAND TUMOR T3N2bM0
63 AANDI 61 MALE 34220 31/3/2009 AYYAR DINDIGUL S.ONCO   9    9  2   9  BEEDIES 25 25TO30   9    9  CARCINOMA LEFT LOWER ALVEOLUS T3N2bM0
 
BIBLIOGRAPHY 
 
• Somers KD, Merrick MA, Lopez ME, et al. Frequent mutations in 
head and neck cancer. Cancer Res 1992;52:5997-6000. 
• Brennan JA, Boyle JO, Koch WM, et al. Association between 
cigarette smoking and mutation of the gene in squamous-cell 
carcinoma of the head and neck. N Engl J Med 1995;332:712-7 
• Chang F, Syrjanen S, Syrjanen K. Implications of the tumor-
suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-
22. 
• Sankaranarayanan R. Oral cancer in India: an epidemiology and 
clinical review.Oral Surg Oral Med Oral Pathol 1990; 69:325-330. 
• Cancers of the Oral cavity and Pharynx in the United States –An 
Epidemiological Overview. J public Health Dent 1996; 56(6): 309-
318. 
• Oral cancer In India: Aetiological factors and prevention. J. Ind. 
Dent. Assoc. 1989; 60 (3): 3-6. 
• Kidwai Memorial Institute of Oncology. Annual report of Hospital 
Cancer Registry: KMIO 1998. 
• Hindle, I., Downer, M.C., and Speight, P.M. The epidemiology of 
oral cancer. Br JOral Maxillofac Surg 1996; 34: 471-476. 
• La Vecchia, C., Tavani, A., Franceschi, S., Levi, F., Corrao, G. and 
Negri, E. Epidemiology and prevention of oral cancer. Oral Oncol, 
Eur J Cancer: 1997; 33 (5): 302-312. 
• Znaor, A., Brennan, P., Gajalakshmi, V., Mathew, A., Shanta, V., 
Varghese, C. and Boffetta, P. Independent and combined effects of 
tobacco smoking, chewing and alcohol drinking on the risk of oral, 
pharyngeal and esophageal cancers in Indians. Oral Oncol, Eur J 
Cancer 2000 Mar; 36(2): 170-174. 
• Balaram, P., Sridhar, H., Rajkumar, T., Vaccarella, S., Herrero, R., 
Nandakumar, A., Ravichandran, K. et al. Oral cancer in southern 
India: the influence of smoking, drinking, pan chewing and oral 
hygiene. Int. J. cancer 2002; 98 (3): 440-445. 
•  Zarbo RJ, Crissman JD. The surgical pathology of head and neck 
cancer. Semin Oncol 1988;15:10-9. 
• J. Trad Wadsworth, MD; Kenneth D. Somers, PhD; Brendan C. 
Stack, Jr, MD; Lisa Cazares, BS; Gunjan Malik, PhD; Bao-Ling 
Adam, PhD; George L. Wright, Jr, PhD; O. John Semmes, PhD; 
Arch Otolaryngol Head Neck Surg. 2004;130:98-104. 
• Navazash.H(1993), Methods for collecting saliva. Annals of the 
New York Academyof Sciences; 694:72-7 
• K.Oshiro et al.,(2007), Preanalytic saliva processing affect 
proteomic results and biomarker screening of head and neck 
squamous carcinoma. International Journal of Oncology. 
Mar;30(3):743-9 
• Balwant Rai.(2007) Oral Fluid in Toxicology. The Internet Journal 
of Toxicolgy. Vol.3  number 2. 
 
